Evome Medical Technologies Executes Non-Binding Letter of Intent to Extend Remaining Simbex Acquisition Debt to June 2025; Increases Sales Targets by 7.5% for Biodex Distribution Contracts; Raises Biodex Product Pricing by 2% for 2024

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) — Evome Medical Technologies Inc. (the “Company” or “Evome”) has executed a non-binding letter of intent (LOI) to extend acquisition debt of US$3,294,440 to the sellers of Simbex, LLC (“Simbex”) to June